Because treatments received by MM group could cause specific immune dysfunction impairing immune response to COVID-19 vaccines, we first compared the levels of specific SARS-CoV-2 IgG antibodies and neutralization capacity in MM patients receiving or not daratumumab (anti-CD38 therapy). The gene discussed is CD38; the disease is Miyoshi myopathy.